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H emophilia is one of the most common inherited bleeding disorders due to the deficiency in clot-
ting factor VIII (hemophilia A) or IX (hemophilia B).  
The estimated frequency of hemophilia is reported 1 in 
5000-10000 birth [1].  Patients with hemophilia have 
been reported to have an increased risk of hepatitis 
virus infection and hepatocellular carcinoma (HCC) due 
to frequent blood transfusions [2].  Repeated transfu-
sions of coagulation factors VIII or IX are known to 
induce the inhibitor of each coagulation factor [3];  
approximately 5% of patients with hemophilia A are 
reported to have the inhibitor to coagulation factor VIII 
[4 , 5].
Several reports have been published focusing on 
hepatectomy for HCC in patients with hemophilia,  
regardless of the high incidence of HCC and hepatitis 
[6-11].  In these previous reports,  no patients under-
went laparoscopic resection,  and only one had the 
inhibitor to coagulation factor VIII [11].  Herein,  we 
report our experience of laparoscopic hepatectomy for a 
patient with hemophilia A with high titer acquired fac-
tor VIII inhibitor.
Case
A 60-year-old man with hemophilia A and transfu-
sion-acquired hepatitis C was diagnosed with HCC in 
segment II.  He was referred to our department of hepa-
tobiliary and pancreatic surgery for liver resection.  The 
tumor was 2.1 cm in diameter and located close to the 
left hepatic vein; next,  laparoscopic left lateral seg-
mentectomy was planned (Fig. 1A , B).  In addition,  the 
patient experienced cholecystitis twice; laparoscopic 
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cholecystectomy was planned simultaneously.  We con-
sulted the hematology department about perioperative 
management of his hemophilia; preoperative blood test 
showed extremely prolonged activated partial thrombo-
plastin time (APTT) (106.8 sec).  He had been treated 
with 2000 IU of full-length recombinant human coagu-
lation factor VIII (ADYNOVATE®,  Takeda,  Tokyo) 
twice a week for his hemophilia A.  Due to The pro-
longed APTT,  inhibitor formation for coagulation fac-
tor VIII was suspected,  and high-titer inhibitor of 
coagulation factor VIII was detected (10 IU/ml).  
Patients with hemophilia without inhibitors or low titer 
inhibitors can be treated with high doses of FVIII or FIX 
for perioperative management; however,  this treat-
ment is ineffective for hemophilia patients with high 
titer inhibitors [12 , 13].  Afterward,  we decided to use 
recombinant activated factor VII (rFVIIa,  NovoSeven®,  
Novo Nordisk,  Bagsvaerd,  Denmark) [11 , 13 , 14] for 
his perioperative management.
Surgical procedure. A camera port was inserted 
through a 12-mm port in the umbilicus,  using the open 
technique;  three additional ports (two 5-mm ports and 
a 12-mm port) were inserted under pneumoperito-
neum (10 mmHg) (Fig. 2A).  Tourniquet method was 
performed,  using a 20 Fr silicone tube during transec-
tion (Fig. 2B).  Liver parenchymal transection with a 
vessel-sealing system (LigaSure®,  Medtronic,  Dublin,  
Iceland) and endoscopic Cavitron ultrasonic surgical 
aspirator (CUSA,  Olympus,  Tokyo,  Japan) were per-
formed after the laparoscopic ultrasound examination,  
along the lateral border of the falciform-round ligament 
(Fig. 2C).  Pedicles of segments II and segment III were 
identified and divided along the transection plane 
(Fig. 2D).  At the end of the resection,  the left hepatic 
vein was exposed and dissected with a vascular stapler 
(Fig. 2E , 2F).
The specimen was placed in the specimen bag.  After 
laparoscopic cholecystectomy,  these specimens were 
delivered through a Pfannenstiel incision.  Two drains 
were inserted through the 5-mm port site and a 20 Fr 
silicone tube inserted hole.  After hemostasis was 
secured,  the ports were removed and the wound 
(including the port site) was closed,  except the drain 
inserted wound.  Total intraoperative blood loss was 
50 ml and total surgery time was 6 h (3.5 h for hepatec-
tomy,  2.5 h for cholecystectomy).
Pre- and perioperative management of hemophilia.
Based on previous reports,  100 μg/kg of rFVIIa per 
dose bolus were administered just before surgery,  and 
bolus injection (100 μg/kg rFVIIa) were administered 
every 2 h during surgery [14 , 15].
Postoperative course. Administration of rFVIIa 
at a dose of 100 μg/kg every 2 h was planned to con-
tinue for 48 h postoperatively.  Twenty four h after sur-
gery,  he was transferred to a general ward from the 
intensive care unit,  without any sign of postoperative 
bleeding; 40 h postoperatively,  subcutaneous hemor-
rhage around the port site (20 Fr silicone tube insertion 
point) and significant decrease in hemoglobin level of 
10.6 g/dl to 6.8 g/dl were observed.  At the time of 




Fig. 1　 (A) Computed tomography (CT) images before liver resection.  Dynamic CT scan showing HCC of 2.1 cm in diameter,  located at 
segment II.  (B) 3D imaging by the Synapse Vincent system (Fuji Film); green transparent area,  regions for planned resection; pink area,  
the portal vein; blue area,  the portal vein,  and the inferior vena cava; red area,  HCC in segment II.
bleeding,  rFVIIa was still injected every two hours.  
Enhanced computed tomography image showed the 
right lateral abdominal wall hematoma around the 
drain tube (placed through the port site) (Fig. 3).  There 
was no intra- or extra-abdominal hemorrhage; only 
intra-abdominal wall hemorrhage was observed.  A total 
transfusion of 840 ml of red cell concentrates was per-
formed.  We decided to continue injecting rFVIIa every 
2 h,  until hemostasis was achieved; 2 days after the 
intra-abdominal wall bleeding,  we confirmed the 
hemostasis and removed both drain tubes placed 
though the port site.  Thick bite sutures were made at 
the port sites to prevent rebleeding from the abdominal 
wall.  Dosage interval of rFVIIa infusion was gradually 
extended 6 days postoperatively (Fig. 4).  We stopped 
the infusion of rFVIIa 17 days postoperatively and 
switched to the injection of emicizumab-kxwh 
(Hemlibra®,  Genentech,  Inc.,  San Francisco, CA,  USA) 








Fig. 2　 (A) Trocar placement for laparoscopic left lateral segmentectomy.  (B) Tourniquet method with a 20 Fr silicone tube.  (C) 
Planned resection line.  (D) Pedicle to segment III was identified and divided.  (E) Left hepatic vein dissection with a vascular stapler.  (F) 
Laparoscopic left lateral segmentectomy is completed.
as a regular therapy for hemophilia.  Emicizumab-kxwh 
is a bispecific humanized monoclonal antibody that 
restores the function of missing activated FVIII by 
bridging activated FIX and FX.  It was approved by the 
Japanese Ministry of Health,  Labor,  and Welfare in 
2018,  for hemophilia A inhibitor patients [16].  He was 
discharged 25 days postoperatively,  without any addi-
tional postoperative bleeding or other complications.  
Hemophilia A has been successfully managed by inject-
ing emicizumab-kxwh; HCC recurrence was not 
observed 1 year postoperatively.
Discussion
Although hemophilia is of the most common inher-
ited bleeding disorders,  most surgeons do not have 
experience with hemophilia A patients.  We believe that 
our experience is worth reporting for other surgeons.  
Guidelines for the management of the patient with 
hemophilia have been published,  and postoperative 
management has been described [13].  However,  pre-
operative management of liver resection with elevated 
risks for bleeding is largely unknown.  Several reports 
have been published about liver resection for patients 
with hemophilia; only one patient with high-titer 
inhibitor of coagulation factor VIII has been reported 
(Table 1) [6-11].  Considering the high risk of hepatitis 
virus infection and HCC [2],  this number of previous 
reports seems to be extremely small.  Surgeons might be 
hesitant to perform liver resection and select other types 
of treatment,  such as radiofrequency ablation (RFA) or 
transcatheter arterial chemoembolization instead.  
However,  liver resection has the greatest therapeutic 
effect on resectable HCC.  Hasegawa et al.  reported the 
therapeutic effect of surgical resection (SR) in the 
Japanese nationwide survey of patients with HCC 
treated by SR,  percutaneous ethanol injection (PEI),  or 
RFA.  The HCC patients who had no more than 3 
tumors and liver damage of class A or B (like our case) 
were analyzed.  The hazard ratio for death was signifi-
cantly lower in the SR group than in the RFA (SR vs. 
RFA: 0.84,  p = 0.006) and PEI groups (SR vs. PEI: 0.75,  
p = 0.0001) [17].  In all previously reported cases and our 
case no severe postoperative complications were noted 
(Clavien-Dindo Classification III-V) [18].  Thus,  liver 
resection can be safely performed in patients with 
hemophilia,  with appropriate perioperative manage-
ment of coagulation factors.
In our case,  the inhibitor development had not been 
detected before preoperative examination for hepatec-
tomy.  The patient had undergone joint replacement 
three times (bilateral total knee and right hip) within 2 
years,  at another hospital.  He was perioperatively 
treated with recombinant factor VIII.  This large amount 
of factor VIII transfusion might result in inhibitor for-
mation.  As per the guidelines,  preoperative assessment 
should include inhibitor screening assay [13].
Patients with hemophilia with low titer inhibitors 
(< 5 BU/ml) can be treated with high doses of FVIII or 
FIX for perioperative management [3 , 12 , 14].  This 
treatment is mostly ineffective for hemophilia patients 
with high titer inhibitors (> 5 BU/ml) (like in our case) 
and likely to induce additional inhibitors.  Our case had 
a high titer inhibitor (10 BU/ml) and bypassing agents 
202 Matsuda et al. Acta Med.  Okayama　Vol.  75,  No.  2
Fig. 3　 Dynamic CT scan showing intra-abdominal wall bleeding 
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Fig. 4　 Summary of post-operative course.  Asterisks indicate PT 
(sec) is unmeasurable due to over coagulation.
should be used for perioperative management [12].  Two 
bypassing agents are currently used: recombinant acti-
vated factor VII (rFVIIa) (NovoSeven®,  Novo Nordisk) 
and activated prothrombin complex concentrate 
(FEIBA,  Shire).  In our case,  we selected rFVIIa as the 
bypassing agent.  The response to these two bypassing 
therapy is different among patients with hemophil-
ia; thus,  preparing both agents is preferable for high 
bleeding risk surgery [12].  FEIBA was used in the pre-
vious case report about hepatectomy for the hemophilia 
patient with high titer factor VIII inhibitor [11].  
Because the patient had always been very responsive to 
FEIBA during his hemophilia bleeds.  The patient was 
infused 50 U/kg of FEIBA twice daily,  from 2 h before 
surgery and continued until discharge.
Development of laparoscopic hepatectomy is rela-
tively slow compared to other abdominal procedures 
due to the complexity of the biliary and vascular struc-
tures and high risk of bleeding.  Advancements in lapa-
roscopic surgery have turned laparoscopic left lateral 
segmentectomy into a standard procedure [19].  The 
advantages of laparoscopic surgery are smaller incision 
and decreased operative blood loss compared to open 
surgery.  We selected the laparoscopic hepatectomy for 
these advantages.  This is the first report on laparo-
scopic hepatectomy for a patient with hemophilia.  We 
did not experience hemostatic difficulty during surgery 
with rFVIIa infusion (total intraoperative blood loss:  
50 ml).  Laparoscopic hepatectomy with appropriate 
perioperative management (including administration of 
the coagulation factor) can be a safe procedure,  even for 
patient with hemophilia.  In our case,  we experienced 
postoperative hemorrhage around the drain site.  We 
closed the wound (including the port site) except for the 
drain inserted into the wound at the time of surgery.  
The drain tube size was smaller than the port site.  
Postoperative hemorrhage could have been prevented if 
the port site was stitched and reefed.
Laparoscopic hepatectomy could be performed in 
this patient,  irrespective of the high FVIII inhibitor 
titer.  The patient experienced postoperative intra- 
abdominal wall hemorrhage which was conservatively 
managed with rFVIIa administration.  The patient is 
alive 12 months postoperatively,  with no evidence of 
HCC recurrence.  We believe that laparoscopic hepatec-
tomy can be even applied for hemophilia patients with 
high titer inhibitors.
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